Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn’s Disease—A Risk-Adjusted Propensity Score Matched Analysis
Early top-down treatment with biologics improves the rates of transmural remission in CD. Risk factors for disabling disease significantly impact the chances of obtaining transmural remission and may help clinicians identify patients suitable for more aggressive treatment strategies.
Authors
- Samuel Fernandes (ORCID: https://orcid.org/0000-0002-2947-8791)
- Helena Cortez‐Pinto (ORCID: https://orcid.org/0000-0002-8537-8744)
- Fernando Magro (ORCID: https://orcid.org/0000-0003-2634-9668)
- Inês Coelho Rodrigues (ORCID: https://orcid.org/0000-0002-7855-501X)
- A Valente (ORCID: https://orcid.org/0000-0003-2116-8294)
- Apollo Vinícius Fernandes Neves (ORCID: https://orcid.org/0009-0004-1224-2776)
- Luís Correia (ORCID: https://orcid.org/0000-0002-3443-5366)
- Ana Rita Gonçalves (ORCID: https://orcid.org/0009-0009-2786-1429)
- S Saraiva (ORCID: https://orcid.org/0000-0001-7153-0322)
- Paula Moura Santos
Institutions
- University of Lisbon (PT)
- Universidade do Porto (PT)
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Centre for Health Technology and Services Research (PT)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/ibd/izaf112
- Citations
- 3
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 5.45